Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results

J Thromb Haemost. 2017 Aug;15(8):1601-1606. doi: 10.1111/jth.13748. Epub 2017 Jul 10.

Abstract

Essentials Prophylaxis is the standard of care for congenital factor XIII-A (FXIII-A) deficiency. Six children with FXIII-A deficiency received once-monthly prophylaxis with recombinant FXIII-A. Prophylaxis was well tolerated and no anti-FXIII antibodies were detected. Prophylaxis was effective with an annualized bleeding rate of zero.

Summary: Background Factor XIII deficiency is a rare, severe congenital bleeding disorder. Monthly prophylaxis with recombinant FXIII A-Subunit (rFXIII) has demonstrated favorable safety and efficacy in patients aged ≥ 6 years, and may similarly benefit younger children. Objective To evaluate the long-term safety and efficacy of rFXIII in children aged < 6 years with congenital FXIII A-subunit deficiency. Patients/methods Six children, who had previously completed a single-dose pharmacokinetic trial of rFXIII, received 35 IU kg-1 rFXIII every 28 days (± 2 days) for a minimum of 52 weeks, and were evaluated for bleeding and adverse events. The Berichrom FXIII activity assay was used to monitor FXIII activity. Results The children, three girls and three boys, had an average age of 3.0 years (range: 1-4 years) at enrollment. The total treatment duration was 1.8-3.5 years, giving a total of 16.6 patient-years. No antibody development, thromboembolic events or allergic reactions occurred. There were 93 mild and seven moderate adverse events. Two adverse events (lymphopenia and gastroenteritis) were reported as probably or possibly related to rFXIII in two children. Two serious adverse events, unrelated to rFXIII, were reported in a single child, each related to head injury, and neither resulting in intracranial hemorrhage. The geometric mean FXIII activity trough was 0.19 IU mL-1 . No bleeding episodes requiring treatment with an FXIII-containing hemostatic agent occurred during the trial; thus, the annualized bleeding rate was 0. Conclusions Consistent with data from older age groups, prophylaxis with rFXIII appears to be safe and effective in young children with congenital FXIII A-subunit deficiency.

Trial registration: ClinicalTrials.gov NCT01253811.

Keywords: factor XIII; factor XIII deficiency; fibrinolysis; prophylaxis; recombinant factor XIII-A subunit.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Child, Preschool
  • Coagulants / administration & dosage*
  • Coagulants / adverse effects
  • Drug Administration Schedule
  • Factor XIII / administration & dosage*
  • Factor XIII / adverse effects
  • Factor XIII Deficiency / blood
  • Factor XIII Deficiency / diagnosis
  • Factor XIII Deficiency / drug therapy*
  • Factor XIII Deficiency / genetics
  • Factor XIIIa / genetics
  • Female
  • Humans
  • Infant
  • Male
  • Recombinant Proteins / administration & dosage
  • Time Factors
  • Treatment Outcome

Substances

  • Coagulants
  • Recombinant Proteins
  • Factor XIII
  • Factor XIIIa

Supplementary concepts

  • Factor Xiii, A Subunit, Deficiency Of

Associated data

  • ClinicalTrials.gov/NCT01253811